Drugs / MEDICLORE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06034041 | Oct 2023 → Mar 2024 | lumbar disk disease | King Chulalongkorn Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03293186 | Jul 2017 → Dec 2020 | — | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mediclore | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06034041 ↗ |
| Modality | Other / unclassified | “Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent” NCT06034041 ↗ |
| Route | Other | “1.5 CC. of Mediclore at the surgical site” NCT06034041 ↗ |